Archive for the ‘Gene Therapy Research’ Category

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Good Start Genetics, Inc., an innovative molecular diagnostics company developing the new gold standard in carrier screening, announced today that it will participate in the 2013 Biotech Showcase in San Francisco, CA. Don Hardison, president and CEO of Good Start Genetics, is scheduled to present Monday, Jan. 7, at 9:45 a.m. (PST).

Don Hardison will be available for one-on-one meetings with investors and media attending the conference.

Event

Date

Time

Place

About Good Start Genetics, Inc.

Good Start Genetics is setting the new gold standard in carrier screening by making testing for the most comprehensive set of known and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable, and affordable tests for all ACOG and ACMG recommended disorders. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price. For more information, please visit http://www.goodstartgenetics.com.

Visit link:
Good Start Genetics to Present at Biotech Showcase in San Francisco

Public release date: 3-Jan-2013 [ | E-mail | Share ]

Contact: Phyllis Edelman pedelman@genetics-gsa.org 301-634-7302 Genetics Society of America

BETHESDA, MD January 3, 2013 The Genetics Society of America (GSA) is pleased to announce the selection of 10 early career researchers five graduate students and five postdoctoral researchers as recipients of a Spring 2013 DeLill Nasser Award for Professional Development in Genetics. The award is a $1,000 travel grant for each researcher to attend any national or international meeting, conference or laboratory course that will enhance his or her career.

"Each round, the review committee has a tough job selecting the most deserving applicants from among the many strong applications," said Adam Fagen, PhD, Executive Director. "These 10 recipients represent just a small sample of the excellence found among grad students and postdocs in our community, ensuring a strong future for the field of genetics."

The DeLill Nasser Award was established by GSA in 2001 to honor its namesake, DeLill Nasser (1929-2000), a long-time GSA member who provided critical support to many early career researchers during her 22 years as program director in eukaryotic genetics at the National Science Foundation. Since the formation of this award, nearly 100 graduate students and postdocs have received funding for travel to further their career goals and enhance their education. The program is supported by GSA, and with charitable donations from members of the genetics community.

The 10 recipients of the spring 2013 DeLill Nasser Awards, their institutions and the conference or lab course each intends to attend are listed below.

Graduate Students

Daniel K. Bricker, University of Utah School of Medicine, Salt Lake City 54th Annual Drosophila Research Conference, April 3-7, 2013, Washington, DC

Russ Corbett-Detig, Harvard University, Cambridge, MA 54th Annual Drosophila Research Conference, April 3-7, 2013, Washington, DC

Maria N. Hindt, Dartmouth College, Hanover, NH International Conference on Arabidopsis, June 24-28, 2013, Sydney, Australia

More:
Genetics Society of America announces Spring 2013 DeLill Nasser Travel Award recipients

SEATTLE, WA--(Marketwire - Jan 3, 2013) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President, will present at the OneMedForum at the Sir Francis Drake Hotel in San Francisco, on Tuesday, January 8, 2013, at 4:00 pm Pacific Time (7:00 pm Eastern Time) and at the Biotech Showcase at the Parc 55 Wyndham Hotel in San Francisco on Wednesday, January 9, 2013, at 10:00 am Pacific Time (1:00 pm Eastern Time). Dr. Quay's presentations will be webcast via the Company's website at http://www.atossagenetics.com.

Dr. Quay stated, "I look forward to presenting our business model, breast health products and services to institutional investors at these prestigious events. I believe the U.S. roll out of our ForeCYTE Breast Health Test and ArgusCYTE Breast Health Test, launch of two additional tests, FullCYTE Breast Health Test and NextCYTE Breast Health Test, and initiation of clinical trials for our intraductal therapy offer investors a compelling investment thesis for 2013 and beyond."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission.All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

More here:
Atossa Genetics to Present at OneMedForum and Biotech Showcase

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) today announced the appointment of Scott Snyder as Chief Marketing Officer. In this role, Scott will spearhead the launch of the companys proprietary PST genetic risk panel to guide more effective dental preventive care. Scott will have responsibility for marketing Interleukins professional healthcare tests, including PST and a proprietary test for osteoarthritis progression, and for the Inherent Health brand of health and wellness genetic tests within consumer channels.

I am very pleased to welcome Scott as Interleukins new Chief Marketing Officer and have great confidence that he will drive the next phase of the Companys growth, said Kenneth Kornman, DDS, PhD, Chief Executive Officer, Interleukin Genetics, Inc. Scotts extensive experience in marketing innovative life sciences products and knowledge of the oral healthcare market are consistent with our companys goal of advancing more personalized care in the prevention of periodontal disease and across all of our wellness programs. He has a proven track record of building valuable brands and driving strong sales performance.

Scott Snyder has nearly 25 years of global consumer marketing experience in life sciences and consumer healthcare. Most recently, Scott served as Vice President of Marketing and General Manager at Bausch & Lomb, Inc. where he led the successful turnaround of the companys global lens care business and directed global franchise management. Prior to this, Scott held marketing leadership roles with Johnson & Johnson, Inc. (J&J) for more than 20 years, including Executive Director of Marketing for Orapharma, Inc. where he successfully led the post-acquisition integration of the dental company into J&J and repositioned the business for further growth. Other positions at J&J included Vice President of Marketing for Therakos, Inc., Director of Managed Care Sales for McNeil Specialty Pharmaceuticals, Inc. and Marketing Director for the Tylenol brand.

I welcome the opportunity to work with Interleukin and its strategic partners to provide the marketing leadership necessary to advance personalized care in dentistry through the regular use of the PST genetic test and personalized medicine overall, said Scott Snyder, Chief Marketing Officer, Interleukin Genetics, Inc.

About Interleukin Genetics

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Certain statements contained herein are forward-looking statements.Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Interleukin Genetics annual report on Form 10-K for the year ended December 31, 2011 and other filings with the Securities and Exchange Commission. Interleukin Genetics disclaims any obligation or intention to update these forward-looking statements.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130103006233/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50520807&lang=en

Read more:
Interleukin Genetics Appoints Scott Snyder as Chief Marketing Officer

Whole-genome Testing and the Possibility of Gene Therapy for Neurological Disorders
(Visit: http://www.uctv.tv Soon everyone can have their genome sequenced. Will this information improve health, or simply clarify our fate? Series: "MIND Institute Lecture Series on Neurodevelopmental Disorders" [Health and Medicine] [Show ID: 24540]

By: UCtelevision

Link:
Whole-genome Testing and the Possibility of Gene Therapy for Neurological Disorders - Video

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute, is pleased to announce the appointment of Keith Knutson, Ph.D., Program Director. Dr. Knutson will be joining VGTI Florida along with several members of his lab. His work will focus on immunotherapeutic approaches in breast and ovarian cancers and how vaccines can boost immunity and help the bodys defense system fight off these cancers.

Dr. Knutson recently received a $3.7 million grant from the National Cancer Institute (NCI) to identify immunologic biomarkers or proteins that could be useful in identifying breast cancer patients who are unlikely to respond to certain therapies. This can help to determine whether a drug used in specific patient groups can be effective or whether these patients should be treated with a different therapeutic regimen.

Cancer is an important area of research focus for VGTI Florida, and Dr. Knutsons work will help make great strides in the understanding and treatment of breast and ovarian cancers, said Jay Nelson, Ph.D., founder and Executive Director of the institute. Dr. Knutson is a leader in his field and we welcome his expertise in treating two serious diseases that affect so many millions of women around the world, said Rafick Pierre Skaly, Ph.D., Chief Scientific Officer and Co-Director of VGTI Florida.

Dr. Knutson is currently the Director of the Ovarian Cancer Immunology and Immunotherapy Program at the Mayo Clinic, Rochester, Minnesota and is also a Member of the U.S. Department of Defenses Breast Cancer Research Program Integration Panel, the primary body that makes decisions on funding. He is the Co-Director of the Mayo Clinic Immune Monitoring Core which is engaged in providing a variety of different immune monitoring and phenotyping services for research purposes across a variety of scientific disciplines including tumor immunology, rheumatoid arthritis, and infectious diseases.

Dr. Knutson has co-authored numerous articles in scientific journals including The Journal of Immunology; The American Journal of Pathology; Cancer Immunology, Immunotherapy and many others. He has a Bachelor of Science in Microbiology from the University of Washington and earned a Ph.D. in pharmacology from the University of Georgia. He completed two postdoctoral fellowships, one in the Division of Medical Oncology, University of Washington and another at the Department of Medicine, University of British Columbia. Following postdoctoral training, Dr. Knutson was awarded the Howard Temin Award from the National Cancer Institute.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer and HIV/AIDS, and infectious diseases. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit http://www.VGTIFL.org.

See original here:
Dr. Keith Knutson Joins the Vaccine & Gene Therapy Institute of Florida as A Research Program Director in Oncology

Neuroscience is the new black, when it comes to fashion in scientific research.

"The gene was the central issue in biology in 20th century," Nobel Laureate Dr. Eric Kandel, neuroscientist at Columbia University said in an interview in Toronto recently. "The mind is the essential issue for biology in the 21st century."

"And certainly if you think of public health consequences, the diseases, pain, schizophrenia, depression, manic depressive disorder, post traumatic stress disorder, God knows what, so many miseries of humankind come from psychiatric and neurological disorders," Kandel added.

Back in the 1960's, when Kandel began his Nobel prize winning work searching for the biological source of memory, neuroscience was a lonely field. "It didn't interest many biologists. Anatomy was considered boring, and electrophysiology was too technically complicated for most scientists to pay attention to," he said.

Richard Beninger is a behavioural neuroscientist at Queen's University, who recalls that as a student he studied the brain as a collection of parts. "You could see white matter and dark matter and lots of fine detail, right down to the neuron level, but it was all morphology, structure," he said.

"But all of that changed, once scientists began to understand the chemical pathways in the brain. The morphology is still there, but now we know what the transmitter systems are. So we have a whole new brain only in the last 40 years to work with," Beninger said.

Today's technology allows scientists to put living, breathing humans into an magnetic resonance imaging machine, tell them to think about something, and watch as the biological traces of thought appear and disappear in colorful bursts, measured by changes in blood oxygen levels. It means scientists can now explore the neural landscape in real time, and chart the cognitive forces that have shaped our species from our earliest days.

As they investigate this neural wonderland, scientists are probing the very essence of what makes us human. It's as though they are lifting the hood of humanity, and tinkering with the wiring to find how what makes us do what we do. And they are discovering that the secret to everything we do, think, or feel, is in that wiring, a constantly changing network of neuronal connections sculpted by evolution and fired by electrical and chemical interactions.

Dr. Kandel calls it the most complex organizational structure in the universe. "So we're far from understanding it completely, very far, but the beginning has been quite dramatic," he says.

"It's certainly extraordinary, our entire experience of life, all of our mental experiences, if they all result from the activity of chemistry in our brain, the activity of neurotransmitters and neurocircuits, it's amazing," Beninger said.

Continue reading here:
Ancient systems in the brain drive human cravings

Sydney, Jan. 2 (ANI): Researchers have found a "genetic switch," that allows them to change breast cancer cells and make them more responsive to treatments like anti-oestrogen therapies, which could help open up new cures for the disease.

Researchers from the Garvan Institute of Medical Research in Sydney found the molecule, known as ELF5, which can turn genes on or off.

By manipulating the molecule, the breast cancer cell's sensitivity to anti-oestrogen drugs used to treat breast cancer could be increased, the Sydney Morning Herald reported.

Oestrogen plays a key role in the breast cancers. Women, who do not experience much oestrogen, either, because they start menstruating later in life or begin menopause early, have a lower risk of having breast cancer.

Led by Professor Ormandy in collaboration with colleagues Maria Kalyga and David Gallego-Ortega, the finding established for the first time that there is a relation between the molecule and breast cancer.

The latest discovery made in collaboration with British researchers, raises the potential for drugs designed to reduce the amount of the molecule in those cancer cells dependent on ELF5 for proliferation.

The study has been outlined in the journal PLOS Biology. (ANI)

Read the rest here:
Gene switch may hold key to fight breast cancer

Tim Boyle/Getty Images

Seven-year-old Gregory White, who suffers from cystic fibrosis, sits in a chair awaiting treatment on April 17, 2002 at the Loyola Oakbrook Medical Center in Oakbrook Terrace, IL.

The promise of genetic medicine is beginning to be fulfilled, but it's been a long, hard slog.

Take the story of Kalydeco. It's designed to treat people with a lung disease called cystic fibrosis. While not quite a cure, the drug is extremely effective for some CF patients.

But the success of Kalydeco has been more than two decades in the making.

A good starting point for the story is Aug. 24, 1989. That's the day scientists from the U.S. and Canada announced the discovery of the gene associated with the disease. It was the early days of gene hunting, and the CF gene was a big prize.

CF is the most common genetic disease in Caucasians. When people inherit a damaged form of the CF gene, a critical protein inside cells doesn't work properly. As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.

The announcement was supposed to be made in conjunction with three papers in the Sept. 8 issue of Science, but a reporter for Reuters got hold of the story early. Science took the unusual step of allowing the scientists to speak to the media before publication.

At the time, scientists predicted that a genetic test for CF was just around the corner. But they also thought a drug to treat the disease was in reach.

The first prediction turned out to be right. "But it wasn't until 20 years later that we were able to find drugs that directly target the underlying cause of cystic fibrosis," says Fred Van Goor, who led the team at what is now Vertex Pharmaceuticals that developed Kalydeco. "So it was a long time between the discovery of the gene and the discovery of Kalyedco."

View post:
Drug fulfills promise of research into Cystic Fibrosis gene

6-3 win against genetics and kurt + codcaster
This video was uploaded from an Android phone.

By: ELIT3xiRoNiiKzZ

Here is the original post:
6-3 win against genetics and kurt + codcaster - Video

George Church (US) - THE BIG PICTURE Symposium - EN
George Church (US) holds a chair in genetics at Harvard Medical School and heads the Center for Computational Genetics. In 1984, he became the first to decode a genome, which led to many other revolutionary discoveries and software developments in the fields of genetic engineering and synthetic biology. http://www.aec.at

By: ArsElectronica

Read more:
George Church (US) - THE BIG PICTURE Symposium - EN - Video

270
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

Read more here:
270 - Video

263
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

Read the rest here:
263 - Video

276
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

See the original post here:
276 - Video

282
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

More here:
282 - Video

251
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

Go here to read the rest:
251 - Video

Advanced Genetics Athlete Melanie Gardner 9 Weeks from 2013 Arnolds
Shoulder Workout I do not own the rights to the music heard in this video. It belongs to the respective copyright owners. I upload these videos to promote the artists to an audience that may not otherwise take notice of the artist and for nothing more. Do NOT duplicate and/or sell this video at any time or to anyone. No copyright infringement intended. If you would like me to remove this video because of any legal issues, please message me and I will promptly and gladly do so

By: Jason Green

Visit link:
Advanced Genetics Athlete Melanie Gardner 9 Weeks from 2013 Arnolds - Video

253
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

Go here to read the rest:
253 - Video

Welcome to the HMGC
Howard Jacob, Ph.D., director and founder of MCW #39;s personalized medicine program at the Human and Molecular Genetics Center, explains personalized medicine and how it will change the face of health care

By: HMGCatMCW

Read the rest here:
Welcome to the HMGC - Video

273
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

Visit link:
273 - Video

286
Oklahoma Bovine Genetics visit obgcattle.com for sale details and to join the mailing list.

By: Tawnia J Misemer

Read this article:
286 - Video

PART 2 PURPLE OG #18 (DNA Genetics) Voyagers Coffeeshop - Amsterdam Weed Review
^ CLICK FOR MORE INFO ^ PLEASE LIKE AND SHARE THIS VIDEO! andrew.pyrah.net Check out my new website - http - Your Site for Amsterdam Coffeeshops, Cannabis Information and Reviews! Thanks for watching! COMMENT and LIKE if you enjoyed the video and SUBSCRIBE to see my new videos as they are released. Need a flight or a hotel in Amsterdam? andrew.pyrah.net HELP SUPPORT THIS CHANNEL Shop Online at EveryoneDoesIt (EDIT) - edit.pyrah.net - Bongs, pipes and more! Or at Weed World - http - Home of Weed World Magazine! Donate via PayPal - http://www.paypal.com - Thanks! FACEBOOK - facebook.com TWITTER - twitter.com @andrewpyrah #PeaceAndPot #AndrewPyrah DAILYBOOTH (Photos) - dailybooth.com MUSIC Intro Music is Bun Up The Sess - youtu.be by Oneroot Freeman - youtube.com Other Music by Kevin MacLeod - incompetech.com Used with permission and thanks to all artists. SPECIAL THANKS TO The Wickit Wand - http Beeline Hemp Wick - TheBeelineStore.com THANKS FOR WATCHING! PEACE AND POT! Head over to http to see more!

By: Andrew Pyrah

Go here to see the original:
PART 2 PURPLE OG #18 (DNA Genetics) Voyagers Coffeeshop - Amsterdam Weed Review - Video

Its hard to get straightforward health guidance from personal genome tests, which are banned in some places. But one way to make them more meaningful is to let more people buy them.

It was easy to send my spit to 23andMe, a personal genetics company based in Mountain View, California. I filled the tube that came by mail with a few milliliters of saliva, mixed in the preservative solution, and screwed on the cap, and my sample was ready to be mailed. Soon I would know my risks for Alzheimers, breast cancer, and obesity, and Id have an idea what medications I should avoid.

Well, not exactly. As in most of human genetics, whats tricky about consumer-friendly tests is interpreting the significance of DNA variation. A couple of weeks after shipping off my tube, I got an e-mail notice that my results were on 23andMes website. While it was fun to click through my ancestry reports, I was less compelled by the analysis of the genetic traits that could influence my health.

The biggest disease risk in my report? I have a 5.2 percent chance of developing restless leg syndrome later in life24 percent greater than the average person, who has a 4.2 percent risk. My risk for Alzheimers is slightly lower than average and my risk for obesity is typical. But these conclusions are not particularly meaningful. New studies could uncover variants in my genome that carry a significant risk for dementia later in life. And for obesity, genetics can be overshadowed by lifestyle.

The results did contain some useful information, however. For example, my genome carries signs that I have an above-average sensitivity to a common blood thinner. Currently, I dont need such a drug, but if that changessay, if I suffer a heart attackthen this knowledge could be critical in helping a physician determine the proper dose of a potentially life-saving medication. I also found motivation to switch to decaffeinated coffeemy report says I am a slow caffeine metabolizer, which is associated with a risk of heart attacks for multi-cup-a-day users like me.

23andMe Personal Genome Service

In some ways, I was lucky that I found nothing monumental in my report. About 40 to 50 percent of customers end up with results like yoursthey dont have anything that jumps out very strongly, says Joanna Mountain, senior director of research at 23andMe. But for many, the results are potentially more significant. For example, for macular degeneration, the risks [that are indicated in the reports] range from 0.1 percent up to 74 percent, Mountain says. For heart disease, theres a big range10 to 50 percent.

It can be difficult for most people to understand what these ranges mean, though. And for now, its not clear how receptive the medical community is to helping. Ive had patients bring me these reports, and I dont spend a lot of time reviewing the results because this is not a test I would have ordered, says Sharon Plon, a geneticist and physician-scientist at Baylor College of Medicine in Houston. Whats missing is proof that these tests can inform and improve patient care, she says: Physicians are going to shy away from using them unless they become part of evidence-based medicine.

Typically, personal genetics companies like 23andMe determine which particular DNA base pairs each customer has at places in the human genome that are known to vary from person to person. The companies then interpret the results of scientific studies to tell customers what their results mean. The tests are sold directly to consumers for as little as a few hundred dollars, without the involvement of a health-care provider. In 2010, the FDA sent letters to several companies warning them that their products were considered medical devices subject to regulation, although exactly how the oversight would happen still hasnt been firmly established. That same year, the Government Accountability Office sent samples to four companies and got conflicting results.

Because interpreting the results is so uncertain and the relationship between genetics and disease risk is sometimes weak in the first place, some critics oppose selling these tests directly to consumers. Such sales are restricted in some countries, such as France, and in a few U.S. states, including New York and Maryland. The American College of Medical Genetics and Genomics stance is that the tests should be taken with guidance from an expert who can assess the validity of the results and explain the actions that could be taken in response, says executive director Michael Watson. New studies on the connection between DNA and disease or drug response are published every week. Some of these studies establish a previously unknown link; others may add more weight to a known association; yet others may contradict or disprove what was once thought to be meaningful. The results of many of these tests are very complex, says Plon.

See original here:
Why We Have a Right to Consumer Genetics

Fiscal Game! SUPER Soldier NIGHTMARE! Violent crime worse in Britain than US
My commentary on the Fiscal cliff foolishness, the ethics of military forces using gene therapy to create mutant soldiers, Japan nationalizing factories and more. DEMCAD2: Emergency Preparation Items Should Be Accessible http://www.youtube.com NonfictionTube http://www.youtube.com Senate-Passed Deal Means Higher Tax on 77% of Households http://www.bloomberg.com CBO Estimates "Obama Tax Cut" To Add $4 Trillion To Deficit Over Next Decade http://www.zerohedge.com Pope #39;s new year address deplores rampant capitalism http://www.bbc.co.uk Japan plans #39;nationalisation #39; of factories to save industry http://www.telegraph.co.uk Violent crime worse in Britain than in US http://www.dailymail.co.uk US on Pace for Slowest Decade of Population Growth Since 1930s http://www.bloomberg.com #39;Tsunami bomb #39; tested off New Zealand coast http://www.telegraph.co.uk Military Must Prep Now for #39;Mutant #39; Future, Researchers Warn http://www.wired.com

By: DEMCAD

Read more:
Fiscal Game! SUPER Soldier NIGHTMARE! Violent crime worse in Britain than US - Video

AUSTRALIAN researchers have found a ''genetic switch'' that could open up new treatments for breast cancer.

The switch allows scientists to change breast cancer cells and make them more responsive to treatments such as anti-oestrogen therapies.

Outlined in the journal PLOS Biology, researchers from the Garvan Institute of Medical Research in Sydney found the molecule, known as ELF5, can turn genes on or off.

By manipulating it, the breast cancer cell's sensitivity to anti-oestrogen drugs used to treat breast cancer can be increased.

Advertisement

''We've made a discovery that concerns the basic biology of breast cancer,'' said Chris Ormandy from the Garvan Institute. ''ELF5 determines whether cells will respond to oestrogen therapy or not.''

Oestrogen plays a key role in breast cancers. Women who do not experience much oestrogen, either because they start menstruating later in life or begin menopause early, have a lower risk of breast cancer.

Led by Professor Ormandy in collaboration with colleagues Maria Kalyga and David Gallego-Ortega, the finding establishes for the first time that there is a link between the molecule and breast cancer.

Found in all breast cells, the molecule was discovered by Professor Ormandy's team in 1999. In 2008 his group showed it triggered milk production in women.

Made with British researchers, the latest discovery raises the potential for drugs designed to reduce the amount of the molecule in those cancer cells dependent on ELF5 for proliferation. Further research could also reduce the incidence of patients undergoing ineffective treatment.

Originally posted here:
'Gene switch' offers hope in breast cancer fight